Robert Lustig: Understanding LDL: Its Atherogenic Potential and the Role of Statins in Treatment?
Robert Lustig frames three central questions: (1) Is LDL the atherogenic particle? (2) Is there another particle more atherogenic than LDL? (3) Do statins alter that risk in primary prevention? He begins by arguing LDL is only partially the atherogenic particle and notes there are multiple LDL types.
Chapters
More from Dr.
Hippocrates said, let thy food be thy medicine #obesity #metabolicsyndrome #lustig #shorts #health
Bill Wilson, MD: Why GLP-1 Drugs Are Overpriced—and How Compounding and Competition Could Fix It
Nitrosamine in Pharmaceutical Products? A Deep Dive into Risk Management by Ron Najafi, Ph.D.
The Subcellular Processes That Belie All Chronic Disease. The Hateful (or Grateful) Eight #lustig
Bill Wilson, MD: GLPs May Reverse Carb Syndrome—Helping Patients Reach Zero and Sustain with Diet
Why Everything You Knew About Obesity Is Wrong | Dr. Robert Lustig on Sugar & Metabolic Syndrome
Robert Lustig, MD: How Fructose Fuels Fatty Liver, Oxidative Stress, and Metabolic Disease #fructose
Robert Lustig, MD: The 3 Types of Fat Fueling Insulin Resistance and Disease #insulin resistance
Bill Wilson, MD: GLPs May Reverse CARB Syndrome. Helping Patients Reach Zero and Sustain with Diet